Efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy-tablet in Japanese children with perennial allergic rhinitis: A randomised, double-blind, placebo-controlled phase 3 trial

被引：0
|
作者：
Okubo, K. [1 ]
Nolte, H. [2 ]
Okamoto, Y. [3 ]
Azuma, R. [4 ]
Natsui, K. [4 ]
Masuyama, K. [5 ]
机构：
[1] Nippon Med Sch, Tokyo, Japan
[2] ALK, Bedminster, NJ USA
[3] Chiba Univ, Chiba, Japan
[4] Torii Pharmaceut, Tokyo, Japan
[5] Yamanashi Univ, Kofu, Yamanashi, Japan
来源：
ALLERGY | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
0603
引用
收藏
页码：322 / 322
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial
    Schuster, Antje
    Caimmi, Davide
    Nolte, Hendrik
    Novakova, Silviya
    Mikler, Jan
    Foss-Skiftesvik, Majken Hougaard
    Osterdal, Anne Sofie
    Emeryk, Andrzej
    Gagnon, Remi
    Pfaar, Oliver
    LANCET REGIONAL HEALTH-EUROPE, 2025, 48
  • [2] Safety profile of the SQ house dust mite (HDM) sublingual immunotherapy-tablet in Japanese adult patients with HDM-induced allergic asthma: A randomized double-blind placebo-controlled phase I trial
    Maekawa, Y.
    Okamiya, K.
    Azuma, R.
    Tanaka, A.
    ALLERGY, 2018, 73 : 326 - 326
  • [3] Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children
    Masuyama, Keisuke
    Okamoto, Yoshitaka
    Okamiya, Kazuhiro
    Azuma, Ryuji
    Fujinami, Toshiaki
    Riis, Bente
    Ohashi-Doi, Katsuyo
    Natsui, Kensuke
    Imai, Toru
    Okubo, Kimihiro
    ALLERGY, 2018, 73 (12) : 2352 - 2363
  • [4] SQ house dust mite sublingual immunotherapy-tablet demonstrated clinically relevant efficacy in Japanese children with allergic rhinitis
    Lawton, S. A.
    Azuma, R.
    Maekawa, Y.
    Natsui, K.
    ALLERGY, 2019, 74 : 683 - 683
  • [5] Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study
    Okamiya, Kazuhiro
    Sekino, Hisakuni
    Azuma, Ryuji
    Kudo, Minoru
    Sakaguchi, Miyuki
    Nemoto, Fumi
    Muramatsu, Naoki
    Maekawa, Yuriko
    Tanaka, Akihiko
    JOURNAL OF ASTHMA, 2019, 56 (12) : 1347 - 1355
  • [6] Safety of Sublingual House Dust Mite (HDM) Immunotherapy: A Randomized, Double-blind, Placebo-controlled US Trial
    Bush, R.
    Swenson, C.
    Fahlberg, B.
    Bernstein, J.
    Gaworski, K.
    Sanchez, H.
    Esch, R.
    Busse, W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S74 - S74
  • [7] House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis
    Bozek, A.
    Ignasiak, B.
    Filipowska, B.
    Jarzab, J.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2013, 43 (02): : 242 - 248
  • [8] Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis
    Okubo, Kimihiro
    Masuyama, Keisuke
    Imai, Toru
    Okamiya, Kazuhiro
    Stage, Brian Sonne
    Seitzberg, Dorthe
    Konno, Akiyoshi
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (06) : 1840 - +
  • [9] Sublingual immunotherapy in primary care in house dust mite allergic children: double-blind randomized, placebo-controlled trial
    de Bot, C.
    Moed, H.
    Berger, M.
    Roder, E.
    Hop, W.
    de Groot, H.
    de Jongste, J.
    van Wijk, Gerth R.
    Bindels, P.
    van der Wouden, J.
    ALLERGY, 2011, 66 : 652 - 652
  • [10] HOUSE DUST MITE SUBLINGUAL-SWALLOW IMMUNOTHERAPY IN PERENNIAL RHINITIS: A DOUBLE-BLIND, PLACEBO-CONTROLLED IRANIAN STUDY
    Hoseini, R. F.
    Jabbari, F.
    Rezaee, A.
    Rafatpanah, H.
    Yousefzadeh, H.
    Ariaee, N.
    Sadri, H.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2018, 32 (01): : 83 - 88
12345